Cantor Fitzgerald Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $160
Benzinga Newsdesk 9 hours ago
Analyst RatingsNewsPrice Target
Cantor Fitzgerald analyst Josh Schimmer maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweight and raises the price target from $155 to $160.
Cantor Fitzgerald analyst Josh Schimmer maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweight and raises the price target from $155 to $160.